Sign in Subscribe

PharmGKB Staff

AMIA 10x10 Virtual Pharmacogenomics course with Stanford University begins June 26, 2017

The American Medical Informatics Association (AMIA) has partnered with the Biomedical Informatics program at Stanford University to present an online course in pharmacogenomics (PGx) as part of the AMIA 10 x 10 series. The course, Pharmacogenomics, will introduce the field and cover topics relevant to PGx including pharmacology, genomics, genome

Curators' Favorite Papers

Concordance between Research Sequencing and Clinical Pharmacogenetic Genotyping in the eMERGE-PGx StudyAuthors: Rasmussen-Torvik LJ, Almoguera B, Doheny KF, Freimuth RR, Gordon AS, Hakonarson H, Hawkins JB, Husami A, Ivacic L, Kullo IJ, Linderman MD, Manolio TA, Obeng AO, Pellegrino R, Prows CA, Ritchie MD, Smith M, Stallings SC, Wolf WA,

IGNITE Network Analysis of Genomic Medicine Implementation Published in BMC Medical Genomics

A new paper in BMC Medical Genomics describes a multi-case study of six IGNITE (Implementing GeNomics In pracTicE) network sites currently implementing genomics, including pharmacogenomics, into patient care. The authors discuss challenges to implementation as well as subsequent strategies to address those challenges. All participating IGNITE institutions cited low prioritization

Curators' Favorite Papers

Electronic medical record-integrated pharmacogenomics and related clinical decision support concepts Authors: Caraballo PJ Bielinski SJ St Sauver JL Weinshilboum RM The authors of this article from Clinical Pharmacology and Therapeutics, discuss the challenges to successful integration of pharmacogenetic/pharmacogenomic (PGx) clinical decision support (CDS) tools into electronic health and medical

NIGMS Director’s Early Career Investigator Lecture on antiretrovirals, PGx

On Wednesday, April 5th at 2:00 PM EST the National Institute of General Medical Sciences (NIGMS) will broadcast the NIGMS Director’s Early Career Investigator Lecture featuring a talk by Dr. Namandjé N. Bumpus entitled “Drug Metabolism, Pharmacogenetics and the Quest to Personalize HIV Treatment and Prevention”. In it,

New Paper shows pharmacogenetic testing drastically reduces ER visits and Readmissions

A new paper published in PLOSOne (Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial by Lindsay S. Elliott et al.) shows the effectiveness of precision medicine. For a year the authors followed a set of eligible

New PharmGKB pathway: macrolide antibiotics pharmacokinetics/pharmacodynamics

The PharmGKB summary of the pharmacokinetics and pharmacodynamics of macrolide antibiotics has been published in Pharmacogenetics and Genomics. This summary introduces the candidate genes involved in the pharmacokinetic and pharmacodynamic pathways of macrolide antibiotics, focusing on erythromycin, clarithromycin, and azithromycin. We present the uptake, transport, metabolism and clearance of the

CPIC Guideline Summary Videos Available on PharmGKB

A new resource is available on PharmGKB to help researchers and clinicians more easily and quickly understand CPIC recommendations and how to find supporting information on the PharmGKB website. Short ~5 minute videos describe the role of the gene(s) and the impact of genetic variation on drug response, provide

Early Registration for Precision Medicine Conference ends Sunday

Early registration for the University of Florida Precision Medicine Conference, held from March 8-10 in Orlando, Florida, ends this Sunday, January 22 at midnight. Earn continuing education credit and learn how to translate pharmacogenomics into practice. The program, which includes speakers, case studies, and participant genotyping, will provide practical information

Response to the American Academy of Pediatrics statement on codeine: let's consider CYP2D6

The American Academy of Pediatrics (AAP) issued a statement last Tuesday that codeine should not be used in children. As discussed in the article, pharmacogenetic variation can affect response to codeine, which is metabolized into its active form by the hepatic enzyme CYP2D6. Thus poor metabolizers are unlikely to benefit